|
|
||||||||||||||
|
|
|||||||||||||||
CANCER |
1 Division of GI Surgery, University Hospital, Nottingham NG7 2UH, UK
2 Cancer Screening Evaluation Unit, Sutton, Surrey SM2 5NG, UK
Correspondence to:
Correspondence to:
Professor J H Scholefield, Division of GI Surgery, University Hospital, Nottingham NG72 UH, UK;
john.scholefield{at}nottingham.ac.uk
Background: Three large randomised trials have shown that screening for colorectal cancer using faecal occult blood (FOB) tests can reduce the mortality from this disease. Two national pilot studies have recently been launched in the UK to investigate the feasibility of population screening for colorectal cancer in the National Health Service. The largest of the randomised trials was conducted in Nottingham and randomised 152 850 individuals between the ages of 45 and 74 years to receive biennial Haemoccult (FOB) test kit (intervention group) or to a control group.
Aims: We have compared the mortality in the intervention group compared with the control group.
Methods: The 152 850 randomised individuals were followed up through local health records and central flagging (Office for National Statistics) over a median follow up period of 11 years.
Results: At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 322%) in the intervention group despite an uptake at first invitation of only approximately 50%. The mortality reduction for those accepting screening was 27%. The reduction in mortality was independent of sex and site of tumour. There was no significant difference in mortality from causes other than colorectal cancer between the intervention and control groups.
Conclusions: Although the reduction in colorectal cancer mortality was sustained, further follow up of this population is required to determine whether a significant reduction in the incidence of colorectal cancer will be achieved.
Keywords: faecal occult blood test; colorectal cancer; screening; mortality
Abbreviations: CRC, colorectal cancer; FOB, faecal occult blood; RR, relative risk; ONS, Office for National Statistics
This article has been cited by other articles:
![]() |
N. Malila, T. Oivanen, O. Malminiemi, and M. Hakama Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design BMJ, November 20, 2008; 337(nov20_2): a2261 - a2261. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., October 15, 2008; (2008) mdn532v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S J Goodyear, E Leung, A Menon, S Pedamallu, N Williams, and L S Wong The effects of population-based faecal occult blood test screening upon emergency colorectal cancer admissions in Coventry and north Warwickshire Gut, February 1, 2008; 57(2): 218 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Knudsen, P. M. McMahon, and G. S. Gazelle Use of Modeling to Evaluate the Cost-Effectiveness of Cancer Screening Programs J. Clin. Oncol., January 10, 2007; 25(2): 203 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
Population screening for colorectal cancer DTB, September 1, 2006; 44(9): 65 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. E. Walsh and J. P. Terdiman Colorectal Cancer Screening: Scientific Review JAMA, March 12, 2003; 289(10): 1288 - 1296. [Abstract] [Full Text] [PDF] |
||||
![]() |
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02) Evid. Based Nurs., January 1, 2003; 6(1): e1 - 1. [Full Text] [PDF] |
||||
![]() |
The Nottingham FOBT Trial: Results of Longer Follow-up Journal Watch Gastroenterology, July 2, 2002; 2002(702): 2 - 2. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |